Podagra, uric acid, and cardiovascular disease

Circulation

Volumn 116, Issue 8, 2007, Pages 880-883

  Alderman, Michael H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ATENOLOL; LOSARTAN; URIC ACID;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EDITORIAL; GOUT; HEALTH CARE COST; HUMAN; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; STROKE;

CARDIOVASCULAR DISEASES; GOUT; HUMANS; PREVALENCE; URIC ACID;

EID: 34548134856     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.728600     Document Type: Editorial

References (34)

1. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900.
2. Mikuls TR, Saag G. New insights into gout epidemiology. Curr Opin Rheumatol. 2006;18:199-203.
3. Brook RA, Kleinman NL, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N. The economic burden of gout on an employed population. Curr Med Res Opin. 2006;22:1381-1389.
4. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(suppl 1):S2.
5. Gertler MM, Gam SM, Levine SA. Serum uric acid in relation to age and physique in health and coronary heart disease. Ann Intern Med. 1951;34:1421-1431.
6. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7-13.
7. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I Epidemiologic Follow-up Study, 1971-1992. JAMA. 2000;283:2404-2410.
8. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid: its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med. 1973;132:401-410.
9. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka MH, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. Arch Intern Med. 2004;164:1546-1551.
10. Chie KL, Hsu HC, Sung FH, Su TC, Chen MF, Lee YT. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: the Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis. 2005;183:147-155.
11. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998;29:635-639.
12. Alderman MH, Cohen H, Madhvan S, Kivlighn A. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999;34:144-150.
13. Anker SD, Doehner W, Rauchhaus M, Shaarma R, Frances D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJS. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997.
14. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation. 2003;107:1951-1953.
15. Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, Vassilopoulos D. Serum uric acid and multiple sclerosis. Clin Neurol Neurosurg. 2006;108:527-531.
16. Campo C, Ruilope LM, Segura J, Rodicio JL, Garcia-Robles R, Garcia-Puig J. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood Press. 2003;12:277-283.
17. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, Vettoretti S, Bezante GP, Del Sette M, Deferrari G, Pontremoli R. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005;45:991-996.
18. Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto JF. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Ann Epidemiol. 1996;6:331-340.
19. Cuspidi C, Valerio C, Sala C, Meani S, Esposito A. Zanchetti A, Mancia G. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens. 2007;20:678-685.
20. Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrerra-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens. 2005;18:431-440.
21. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-1190.
22. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol. 2002;282:F991-F997.
23. Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol. 2002;283:F1105-F1110.
24. Saito I, Saruta T, Kondon K, Nakamura R, Oquro T, Yamagami K, Ozawa Y, Kato E. Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc. 1978;26:241-247.
25. Waring WS, Webb DJ, Maxwell SRJ. Effect of local hyperuricemia on endothelial function in the human forearm vascular bed. Br J Clin Pharmacol. 2000;49:511.
26. Suarna C, Dean RT, May J, Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol. 1995;15:1616-1624.
27. Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study: Atherosclerosis Risk in Communities. Stroke. 1999;29:635-639.
28. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle proliferation by increasing platelet derived growth factor A-chain expression. J Biol Chem. 1991;266:8604-8608.
29. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816-826.
30. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire L, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Bahlof B. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041-1049.
31. Doehner V, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJS, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo- controlled studies. Circulation. 2002;105:2619-2624.
32. Coghlan JG, Flitter WD, Clutton SM, Panda R, Daly R, Wright G, Ilsley CD, Slater TF. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1994;107:248-256.
33. Weimert NA, Tanke WF, Sims JJ. Allopurinol as a cardioprotective during coronary artery bypass graft surgery. Ann Pharmacother. 2003;37:1708-1711.
34. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, Marban E, Hare JM. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411.